PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma

NCT03387943 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Poorly Differentiated Thyroid Carcinoma

Interventions

DRUG: PLD
DRUG: Cisplatin

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.